Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 554

1.

Developing therapeutic strategies to promote myelin repair in multiple sclerosis.

Baldassari LE, Feng J, Clayton BLL, Oh SH, Sakaie K, Tesar PJ, Wang Y, Cohen JA.

Expert Rev Neurother. 2019 Jun 19. doi: 10.1080/14737175.2019.1632192. [Epub ahead of print]

PMID:
31215271
2.

Longitudinal changes in brain function associated with symptom improvement in youth with PTSD.

Garrett A, Cohen JA, Zack S, Carrion V, Jo B, Blader J, Rodriguez A, Vanasse TJ, Reiss AL, Agras WS.

J Psychiatr Res. 2019 Jul;114:161-169. doi: 10.1016/j.jpsychires.2019.04.021. Epub 2019 Apr 27.

PMID:
31082658
3.

Depression in Maltreated Children and Adolescents.

De Bellis MD, Nooner KB, Scheid JM, Cohen JA.

Child Adolesc Psychiatr Clin N Am. 2019 Jul;28(3):289-302. doi: 10.1016/j.chc.2019.02.002. Epub 2019 Apr 4. Review.

PMID:
31076108
4.

The emergence of follow-on disease-modifying therapies for multiple sclerosis.

Moss BP, Cohen JA.

Mult Scler. 2019 May 10:1352458519845106. doi: 10.1177/1352458519845106. [Epub ahead of print]

PMID:
31074707
5.

Trauma-Focused Cognitive Behavioral Therapy for Childhood Traumatic Separation.

Cohen JA, Mannarino AP.

Child Abuse Negl. 2019 Jun;92:179-195. doi: 10.1016/j.chiabu.2019.03.006. Epub 2019 Apr 15.

PMID:
30999167
6.

Misclassification of Myocardial Injury as Myocardial Infarction: Implications for Assessing Outcomes in Value-Based Programs.

McCarthy C, Murphy S, Cohen JA, Rehman S, Jones-O'Connor M, Olshan DS, Singh A, Vaduganathan M, Januzzi JL Jr, Wasfy JH.

JAMA Cardiol. 2019 Mar 17. doi: 10.1001/jamacardio.2019.0716. [Epub ahead of print]

PMID:
30879022
7.

Movement disorders in early MS and related diseases: A prospective observational study.

Abboud H, Yu XX, Knusel K, Fernandez HH, Cohen JA.

Neurol Clin Pract. 2019 Feb;9(1):24-31. doi: 10.1212/CPJ.0000000000000560.

PMID:
30859004
8.

Underutilization of Cardiac Rehabilitation for Type 2 Myocardial Infarction.

McCarthy CP, Murphy S, Cohen JA, Rehman S, Jones-O'Connor M, Olshan DS, Singh A, Vaduganathan M, Januzzi JL Jr, Wasfy JH.

J Am Coll Cardiol. 2019 Apr 23;73(15):2005-2007. doi: 10.1016/j.jacc.2019.01.032. Epub 2019 Mar 4. No abstract available.

PMID:
30846342
9.

Pilot Evaluation of a Tablet-Based Application to Improve Quality of Care in Child Mental Health Treatment.

Davidson TM, Bunnell BE, Saunders BE, Hanson RF, Danielson CK, Cook D, Chu BC, Dorsey S, Adams ZW, Andrews AR 3rd, Walker JH, Soltis KE, Cohen JA, Deblinger E, Ruggiero KJ.

Behav Ther. 2019 Mar;50(2):367-379. doi: 10.1016/j.beth.2018.07.005. Epub 2018 Jul 27.

10.

Knowledge of radiation legislation and guidelines amongst foundation doctors is inadequate for safe practice in the current era of radiology.

Cohen JA.

Clin Radiol. 2019 Jun;74(6):418-420. doi: 10.1016/j.crad.2019.01.020. Epub 2019 Feb 23. Review.

PMID:
30803812
11.

Autologous Hematopoietic Cell Transplantation for Treatment-Refractory Relapsing Multiple Sclerosis: Position Statement from the American Society for Blood and Marrow Transplantation.

Cohen JA, Baldassari LE, Atkins HL, Bowen JD, Bredeson C, Carpenter PA, Corboy JR, Freedman MS, Griffith LM, Lowsky R, Majhail NS, Muraro PA, Nash RA, Pasquini MC, Sarantopoulos S, Savani BN, Storek J, Sullivan KM, Georges GE.

Biol Blood Marrow Transplant. 2019 May;25(5):845-854. doi: 10.1016/j.bbmt.2019.02.014. Epub 2019 Feb 19. Review.

12.

Spinal cord involvement in multiple sclerosis and neuromyelitis optica spectrum disorders.

Ciccarelli O, Cohen JA, Reingold SC, Weinshenker BG; International Conference on Spinal Cord Involvement and Imaging in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders.

Lancet Neurol. 2019 Feb;18(2):185-197. doi: 10.1016/S1474-4422(18)30460-5. Review.

PMID:
30663608
13.

The FLUENT study design: investigating immune cell subset and neurofilament changes in patients with relapsing multiple sclerosis treated with fingolimod.

Cohen JA, Bar-Or A, Cree BAC, Mao-Draayer Y, Han MH, Singer B, Jannu A, Kolodny S, Meng X, Winger RC.

Mult Scler J Exp Transl Clin. 2019 Jan 2;5(1):2055217318819245. doi: 10.1177/2055217318819245. eCollection 2019 Jan-Mar.

14.

Follow-on glatiramer acetate.

Cohen JA, Wolf C, Selmaj K, Arends R.

eNeurologicalSci. 2018 Nov 23;13:51-52. doi: 10.1016/j.ensci.2018.11.019. eCollection 2018 Dec. No abstract available.

15.

Polygenic adaptation and convergent evolution on growth and cardiac genetic pathways in African and Asian rainforest hunter-gatherers.

Bergey CM, Lopez M, Harrison GF, Patin E, Cohen JA, Quintana-Murci L, Barreiro LB, Perry GH.

Proc Natl Acad Sci U S A. 2018 Nov 27;115(48):E11256-E11263. doi: 10.1073/pnas.1812135115. Epub 2018 Nov 9.

16.

Genetic findings in adolescent and adult-onset leukodystrophies with hypomyelinating features.

Macaron G, Samaan S, Cohen JA, Nadjar Y.

J Neurol Neurosurg Psychiatry. 2019 Jul;90(7):836-838. doi: 10.1136/jnnp-2018-319214. Epub 2018 Nov 2. No abstract available.

PMID:
30389777
17.

Symbol Digit Modalities Test: A valid clinical trial endpoint for measuring cognition in multiple sclerosis.

Strober L, DeLuca J, Benedict RH, Jacobs A, Cohen JA, Chiaravalloti N, Hudson LD, Rudick RA, LaRocca NG; Multiple Sclerosis Outcome Assessments Consortium (MSOAC).

Mult Scler. 2018 Oct 18:1352458518808204. doi: 10.1177/1352458518808204. [Epub ahead of print]

PMID:
30334474
18.

Infection risk with alemtuzumab decreases over time: pooled analysis of 6-year data from the CAMMS223, CARE-MS I, and CARE-MS II studies and the CAMMS03409 extension study.

Wray S, Havrdova E, Snydman DR, Arnold DL, Cohen JA, Coles AJ, Hartung HP, Selmaj KW, Weiner HL, Daizadeh N, Margolin DH, Chirieac MC, Compston DAS.

Mult Scler. 2018 Oct 5:1352458518796675. doi: 10.1177/1352458518796675. [Epub ahead of print]

PMID:
30289355
19.

Discontinuation and comparative effectiveness of dimethyl fumarate and fingolimod in 2 centers.

Vollmer B, Ontaneda D, Bandyopadhyay A, Cohn S, Nair K, Sillau S, Bermel RA, Corboy JR, Fox RJ, Vollmer T, Cohen JA, Alvarez E, Hersh CM.

Neurol Clin Pract. 2018 Aug;8(4):292-301. doi: 10.1212/CPJ.0000000000000487.

20.

Helping Children With Traumatic Reactions to Parental Suicide.

Cohen JA, Mannarino AP.

J Am Acad Child Adolesc Psychiatry. 2018 Aug;57(8):619. doi: 10.1016/j.jaac.2018.05.009.

PMID:
30071985
21.

Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study.

Cohen JA, Comi G, Arnold DL, Bar-Or A, Selmaj KW, Steinman L, Havrdová EK, Cree BA, Montalbán X, Hartung HP, Huang V, Frohna P, Skolnick BE, Kappos L; RADIANCE Trial Investigators.

Mult Scler. 2018 Jul 25:1352458518789884. doi: 10.1177/1352458518789884. [Epub ahead of print]

PMID:
30043658
22.

Integrating multiple sclerosis guidelines into practice.

Macaron G, Cohen JA.

Lancet Neurol. 2018 Aug;17(8):658-660. doi: 10.1016/S1474-4422(18)30248-5. Epub 2018 Jul 17. No abstract available.

PMID:
30033052
23.

Applying the 2017 McDonald diagnostic criteria for multiple sclerosis - Authors' reply.

Thompson AJ, Reingold SC, Cohen JA; International Panel on Diagnosis of Multiple Sclerosis.

Lancet Neurol. 2018 Jun;17(6):499-500. doi: 10.1016/S1474-4422(18)30168-6. No abstract available.

PMID:
29778360
24.

Feasibility of mesenchymal stem cell culture expansion for a phase I clinical trial in multiple sclerosis.

Planchon SM, Lingas KT, Reese Koç J, Hooper BM, Maitra B, Fox RM, Imrey PB, Drake KM, Aldred MA, Lazarus HM, Cohen JA.

Mult Scler J Exp Transl Clin. 2018 Mar 26;4(1):2055217318765288. doi: 10.1177/2055217318765288. eCollection 2018 Jan-Mar.

25.

Neuromuscular diseases associated with Human Immunodeficiency Virus infection.

Prior DE, Song N, Cohen JA.

J Neurol Sci. 2018 Apr 15;387:27-36. doi: 10.1016/j.jns.2018.01.016. Epub 2018 Jan 31. Review.

PMID:
29571868
26.

Being in-between: A model of cultural identity negotiation for emerging adult immigrants.

Cohen JA, Kassan A.

J Couns Psychol. 2018 Mar;65(2):133-154. doi: 10.1037/cou0000265.

PMID:
29543472
27.

Mesenchymal Stem Cell-derived Neural Progenitor Cells in Progressive Multiple Sclerosis: Great Expectations.

Baldassari LE, Cohen JA.

EBioMedicine. 2018 Mar;29:5-6. doi: 10.1016/j.ebiom.2018.02.021. Epub 2018 Feb 23. No abstract available.

28.

Safety and efficacy of ADS-5102 (amantadine) extended release capsules to improve walking in multiple sclerosis: A randomized, placebo-controlled, phase 2 trial.

Cohen JA, Hunter SF, Brown TR, Gudesblatt M, Thrower BW, Llorens L, Souza-Prien CJ, Ruby AE, Chernoff DN, Patni R.

Mult Scler. 2019 Apr;25(4):601-609. doi: 10.1177/1352458518754716. Epub 2018 Jan 25.

PMID:
29368539
29.
30.
31.

Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria.

Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, Correale J, Fazekas F, Filippi M, Freedman MS, Fujihara K, Galetta SL, Hartung HP, Kappos L, Lublin FD, Marrie RA, Miller AE, Miller DH, Montalban X, Mowry EM, Sorensen PS, Tintoré M, Traboulsee AL, Trojano M, Uitdehaag BMJ, Vukusic S, Waubant E, Weinshenker BG, Reingold SC, Cohen JA.

Lancet Neurol. 2018 Feb;17(2):162-173. doi: 10.1016/S1474-4422(17)30470-2. Epub 2017 Dec 21. Review.

PMID:
29275977
32.

Adjunctive Therapies for Catheter Ablation of Non-Paroxysmal Atrial Fibrillation.

Cohen JA, Mansour M.

J Atr Fibrillation. 2016 Dec 31;9(4):1490. doi: 10.4022/jafib.1490. eCollection 2016 Dec. Review.

33.

Comorbidities in MS are associated with treatment intolerance and disability.

McDonnell GV, Cohen JA.

Neurology. 2017 Nov 28;89(22):2218-2219. doi: 10.1212/WNL.0000000000004699. Epub 2017 Nov 1. No abstract available.

PMID:
29093072
34.

Understanding the positive benefit:risk profile of alemtuzumab in relapsing multiple sclerosis: perspectives from the Alemtuzumab Clinical Development Program.

Havrdova E, Cohen JA, Horakova D, Kovarova I, Meluzinova E.

Ther Clin Risk Manag. 2017 Oct 16;13:1423-1437. doi: 10.2147/TCRM.S143509. eCollection 2017. Review.

35.

Early versus late Gamma Knife radiosurgery following transsphenoidal surgery for nonfunctioning pituitary macroadenomas: a multicenter matched-cohort study.

Pomeraniec IJ, Kano H, Xu Z, Nguyen B, Siddiqui ZA, Silva D, Sharma M, Radwan H, Cohen JA, Dallapiazza RF, Iorio-Morin C, Wolf A, Jane JA, Grills IS, Mathieu D, Kondziolka D, Lee CC, Wu CC, Cifarelli CP, Chytka T, Barnett GH, Lunsford LD, Sheehan JP.

J Neurosurg. 2018 Sep;129(3):648-657. doi: 10.3171/2017.5.JNS163069. Epub 2017 Oct 27.

PMID:
29076785
36.

Merkel cell carcinoma with fingolimod treatment for multiple sclerosis: A case report.

Mahajan KR, Ko JS, Tetzlaff MT, Hudgens CW, Billings SD, Cohen JA.

Mult Scler Relat Disord. 2017 Oct;17:12-14. doi: 10.1016/j.msard.2017.06.004. Epub 2017 Jun 22.

PMID:
29055440
37.

Cell-based therapeutic strategies for multiple sclerosis.

Scolding NJ, Pasquini M, Reingold SC, Cohen JA; International Conference on Cell-Based Therapies for Multiple Sclerosis; International Conference on Cell-Based Therapies for Multiple Sclerosis; International Conference on Cell-Based Therapies for Multiple Sclerosis.

Brain. 2017 Nov 1;140(11):2776-2796. doi: 10.1093/brain/awx154. Review.

38.

Clinical outcome measures for progressive MS trials.

Ontaneda D, Cohen JA, Amato MP.

Mult Scler. 2017 Oct;23(12):1627-1635. doi: 10.1177/1352458517729465. Review.

PMID:
29041863
39.

Clemastine fumarate for promotion of optic nerve remyelination.

Cohen JA, Tesar PJ.

Lancet. 2017 Dec 2;390(10111):2421-2422. doi: 10.1016/S0140-6736(17)32639-9. Epub 2017 Oct 10. No abstract available.

PMID:
29029894
40.

Multiple Sclerosis: Unprecedented Progress But Significant Challenges Ahead.

Conway DS, Hua LH, Cohen JA.

Neurotherapeutics. 2017 Oct;14(4):832-834. doi: 10.1007/s13311-017-0576-1. No abstract available.

41.

Comparative efficacy and discontinuation of dimethyl fumarate and fingolimod in clinical practice at 24-month follow-up.

Hersh CM, Love TE, Bandyopadhyay A, Cohn S, Hara-Cleaver C, Bermel RA, Fox RJ, Cohen JA, Ontaneda D.

Mult Scler J Exp Transl Clin. 2017 Aug 24;3(3):2055217317715485. doi: 10.1177/2055217317715485. eCollection 2017 Jul-Sep.

42.

A Pilot Study of Trauma-Focused Cognitive-Behavioral Therapy Delivered via Telehealth Technology.

Stewart RW, Orengo-Aguayo RE, Cohen JA, Mannarino AP, de Arellano MA.

Child Maltreat. 2017 Nov;22(4):324-333. doi: 10.1177/1077559517725403. Epub 2017 Sep 4.

PMID:
28868894
43.

Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings.

Coles AJ, Cohen JA, Fox EJ, Giovannoni G, Hartung HP, Havrdova E, Schippling S, Selmaj KW, Traboulsee A, Compston DAS, Margolin DH, Thangavelu K, Chirieac MC, Jody D, Xenopoulos P, Hogan RJ, Panzara MA, Arnold DL; CARE-MS II and CAMMS03409 Investigators.

Neurology. 2017 Sep 12;89(11):1117-1126. doi: 10.1212/WNL.0000000000004354. Epub 2017 Aug 23.

44.

Alemtuzumab CARE-MS I 5-year follow-up: Durable efficacy in the absence of continuous MS therapy.

Havrdova E, Arnold DL, Cohen JA, Hartung HP, Fox EJ, Giovannoni G, Schippling S, Selmaj KW, Traboulsee A, Compston DAS, Margolin DH, Thangavelu K, Rodriguez CE, Jody D, Hogan RJ, Xenopoulos P, Panzara MA, Coles AJ; CARE-MS I and CAMMS03409 Investigators.

Neurology. 2017 Sep 12;89(11):1107-1116. doi: 10.1212/WNL.0000000000004313. Epub 2017 Aug 23. Erratum in: Neurology. 2018 Apr 17;90(16):755.

45.

Sphingosine 1-Phosphate Receptor Modulators for the Treatment of Multiple Sclerosis.

Chaudhry BZ, Cohen JA, Conway DS.

Neurotherapeutics. 2017 Oct;14(4):859-873. doi: 10.1007/s13311-017-0565-4. Review.

46.

The MSOAC approach to developing performance outcomes to measure and monitor multiple sclerosis disability.

LaRocca NG, Hudson LD, Rudick R, Amtmann D, Balcer L, Benedict R, Bermel R, Chang I, Chiaravalloti ND, Chin P, Cohen JA, Cutter GR, Davis MD, DeLuca J, Feys P, Francis G, Goldman MD, Hartley E, Kapoor R, Lublin F, Lundstrom G, Matthews PM, Mayo N, Meibach R, Miller DM, Motl RW, Mowry EM, Naismith R, Neville J, Panagoulias J, Panzara M, Phillips G, Robbins A, Sidovar MF, Smith KE, Sperling B, Uitdehaag BM, Weaver J; Multiple Sclerosis Outcome Assessments Consortium (MSOAC).

Mult Scler. 2018 Oct;24(11):1469-1484. doi: 10.1177/1352458517723718. Epub 2017 Aug 11.

47.

Trauma-Focused Cognitive Behavioral Therapy for Commercially Sexually Exploited Youth.

Cohen JA, Mannarino AP, Kinnish K.

J Child Adolesc Trauma. 2017 Jun;10(2):175-185. doi: 10.1007/s40653-015-0073-9. Epub 2015 Dec 28.

48.

Therapeutic Targets for Multiple Sclerosis: Current Treatment Goals and Future Directions.

Smith AL, Cohen JA, Hua LH.

Neurotherapeutics. 2017 Oct;14(4):952-960. doi: 10.1007/s13311-017-0548-5. Review.

49.

Pilot trial of intravenous autologous culture-expanded mesenchymal stem cell transplantation in multiple sclerosis.

Cohen JA, Imrey PB, Planchon SM, Bermel RA, Fisher E, Fox RJ, Bar-Or A, Sharp SL, Skaramagas TT, Jagodnik P, Karafa M, Morrison S, Reese Koc J, Gerson SL, Lazarus HM.

Mult Scler. 2018 Apr;24(4):501-511. doi: 10.1177/1352458517703802. Epub 2017 Apr 6.

50.

Top 50 most-cited articles on craniovertebral junction surgery.

Alan N, Cohen JA, Zhou J, Pease M, Kanter AS, Okonkwo DO, Hamilton DK.

J Craniovertebr Junction Spine. 2017 Jan-Mar;8(1):22-32. doi: 10.4103/0974-8237.199883.

Supplemental Content

Loading ...
Support Center